Sat Feb 15 06:39:14 UTC 2025: ## ICMR Seeks Partners to Commercialize New Typhoid and Paratyphoid Vaccine
**NEW DELHI, February 15, 2025** – The Indian Council of Medical Research (ICMR) has issued a call for expressions of interest (EoI) from organizations and companies to collaborate on the development and commercialization of a new typhoid and paratyphoid vaccine. The vaccine, developed by the ICMR-National Institute for Research in Bacterial Infections (NIRBI), targets *Salmonella Typhi* and *Salmonella Paratyphi*, the bacteria responsible for these debilitating illnesses.
Typhoid fever remains a significant public health concern in India, with an estimated 4.5 million cases annually. The ICMR’s new vaccine technology offers a potential solution to this widespread problem. Selected partners will be responsible for the vaccine’s further development, regulatory compliance, and commercialization. In return, they will pay a 2% royalty on net sales to the ICMR.
The EoI process will evaluate applicants based on their research and development capabilities. Successful candidates will receive expert guidance and technical support from ICMR-NIRBI throughout the development process, including assistance with study planning, product development, and safety and efficacy assessments. The collaboration will begin with a Phase I scientific/technical validation, requiring the signing of a non-disclosure agreement (NDA).
This initiative aims to accelerate the availability of a crucial new vaccine to combat typhoid and paratyphoid fever in India and potentially worldwide. The ICMR hopes this partnership will significantly improve public health outcomes and address the substantial burden of these diseases.
First Piper 